X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi), supplied by Coherus, as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC).
Lead Product(s): INO-3112,Toripalimab
Therapeutic Area: Oncology Product Name: INO-3112
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
INO-3107 is designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins. It is being evaluated in phase 1/2 clinical trials for the treatment of Recurrent Respiratory Papillomatosis (RRP).
Lead Product(s): INO-3107
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INO-3107
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
INO-3107 is clinical-stage DNA medicine product candidate being developed as a potential treatment for RRP. it is designed to elicit a targeted T cell response against HPV-6 and HPV-11, the HPV types responsible for causing RRP among other HPV-related diseases.
Lead Product(s): INO-3107
Therapeutic Area: Rare Diseases and Disorders Product Name: INO-3107
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
INO-3107 is clinical-stage DNA medicine product candidate being developed as a potential treatment for RRP. INO-3107 is designed to elicit a targeted T cell response against HPV-6 and HPV-11, the HPV types responsible for causing RRP among other HPV-related diseases.
Lead Product(s): INO-3107
Therapeutic Area: Rare Diseases and Disorders Product Name: INO-3107
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
INO-3107 induces cellular responses against both HPV 6 and HPV 11, inducing both activated CD4 and activated lytic CD8 T cells. It is being investigated for HPV 6 and HPV 11-associated recurrent respiratory papillomatosis in adults.
Lead Product(s): INO-3107
Therapeutic Area: Rare Diseases and Disorders Product Name: INO-3107
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
INO-3107 induces cellular responses against both HPV 6 and HPV 11, inducing both activated CD4 and activated lytic CD8 T cells. It is being investigated for HPV 6 and HPV 11-associated recurrent respiratory papillomatosis in adults.
Lead Product(s): INO-3107
Therapeutic Area: Infections and Infectious Diseases Product Name: INO-3107
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
INO-4201 is a DNA vaccine targeting Zaire Ebola virus glycoprotein. It encodes for a synthetic consensus antigen that encompasses ZEBOV genetic variability from various outbreak strains to broaden immune coverage for divergent ZEBOV virus variants.
Lead Product(s): INO-4201
Therapeutic Area: Infections and Infectious Diseases Product Name: INO-4201
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
INO-4500 is a DNA vaccine candidate, administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA™ 2000 device in Ghana. The dosing regimen involved two intradermal vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg doses.
Lead Product(s): INO-4500
Therapeutic Area: Infections and Infectious Diseases Product Name: INO-4500
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
INO-4800 is a DNA medicine product candidate that has been studied as a heterologous booster vaccine candidate for COVID-19. The INO-4800 vaccine contains the plasmid pGX9501, which encodes for the entire length of the Spike glycoprotein of SARS-CoV-2.
Lead Product(s): INO-4800
Therapeutic Area: Infections and Infectious Diseases Product Name: INO-4800
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trial.
Lead Product(s): INO-3107
Therapeutic Area: Infections and Infectious Diseases Product Name: INO-3107
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
